S&P 500   4,548.98 (-0.03%)
DOW   35,397.12 (+0.18%)
QQQ   389.19 (+0.01%)
AAPL   189.94 (+0.08%)
MSFT   381.25 (+0.70%)
META   336.24 (+0.46%)
GOOGL   136.64 (+0.17%)
AMZN   147.02 (-0.48%)
TSLA   245.39 (+3.94%)
NVDA   476.51 (-1.23%)
NIO   7.21 (+0.28%)
BABA   76.33 (-1.55%)
AMD   121.45 (-0.98%)
T   16.11 (-0.62%)
F   10.34 (+0.00%)
MU   75.12 (-3.08%)
CGC   0.53 (-2.87%)
GE   118.92 (-0.88%)
DIS   93.57 (-1.68%)
AMC   6.66 (-2.06%)
PFE   29.74 (-1.33%)
PYPL   58.40 (+3.56%)
XOM   104.26 (+0.29%)
S&P 500   4,548.98 (-0.03%)
DOW   35,397.12 (+0.18%)
QQQ   389.19 (+0.01%)
AAPL   189.94 (+0.08%)
MSFT   381.25 (+0.70%)
META   336.24 (+0.46%)
GOOGL   136.64 (+0.17%)
AMZN   147.02 (-0.48%)
TSLA   245.39 (+3.94%)
NVDA   476.51 (-1.23%)
NIO   7.21 (+0.28%)
BABA   76.33 (-1.55%)
AMD   121.45 (-0.98%)
T   16.11 (-0.62%)
F   10.34 (+0.00%)
MU   75.12 (-3.08%)
CGC   0.53 (-2.87%)
GE   118.92 (-0.88%)
DIS   93.57 (-1.68%)
AMC   6.66 (-2.06%)
PFE   29.74 (-1.33%)
PYPL   58.40 (+3.56%)
XOM   104.26 (+0.29%)
S&P 500   4,548.98 (-0.03%)
DOW   35,397.12 (+0.18%)
QQQ   389.19 (+0.01%)
AAPL   189.94 (+0.08%)
MSFT   381.25 (+0.70%)
META   336.24 (+0.46%)
GOOGL   136.64 (+0.17%)
AMZN   147.02 (-0.48%)
TSLA   245.39 (+3.94%)
NVDA   476.51 (-1.23%)
NIO   7.21 (+0.28%)
BABA   76.33 (-1.55%)
AMD   121.45 (-0.98%)
T   16.11 (-0.62%)
F   10.34 (+0.00%)
MU   75.12 (-3.08%)
CGC   0.53 (-2.87%)
GE   118.92 (-0.88%)
DIS   93.57 (-1.68%)
AMC   6.66 (-2.06%)
PFE   29.74 (-1.33%)
PYPL   58.40 (+3.56%)
XOM   104.26 (+0.29%)
S&P 500   4,548.98 (-0.03%)
DOW   35,397.12 (+0.18%)
QQQ   389.19 (+0.01%)
AAPL   189.94 (+0.08%)
MSFT   381.25 (+0.70%)
META   336.24 (+0.46%)
GOOGL   136.64 (+0.17%)
AMZN   147.02 (-0.48%)
TSLA   245.39 (+3.94%)
NVDA   476.51 (-1.23%)
NIO   7.21 (+0.28%)
BABA   76.33 (-1.55%)
AMD   121.45 (-0.98%)
T   16.11 (-0.62%)
F   10.34 (+0.00%)
MU   75.12 (-3.08%)
CGC   0.53 (-2.87%)
GE   118.92 (-0.88%)
DIS   93.57 (-1.68%)
AMC   6.66 (-2.06%)
PFE   29.74 (-1.33%)
PYPL   58.40 (+3.56%)
XOM   104.26 (+0.29%)

Vaccinex Stock Price, News & Analysis (NASDAQ:VCNX)

$0.82
-0.04 (-5.00%)
(As of 01:58 PM ET)
Compare
Today's Range
$0.77
$0.87
50-Day Range
$0.82
$2.39
52-Week Range
$0.77
$12.36
Volume
105,099 shs
Average Volume
194,457 shs
Market Capitalization
$10.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Vaccinex MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.89mentions of Vaccinex in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$3 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars


VCNX stock logo

About Vaccinex Stock (NASDAQ:VCNX)

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.

VCNX Stock Price History

VCNX Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Why Is Vaccinex (VCNX) Stock Up 26% Today?
Vaccinex Shares Slide Premarket After Stock Offering
Vaccinex Announces Pricing of $9.6 Million Public Offering
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Vaccinex Recent Insider Activity
Vaccinex Board to Implement 1-for-15 Reverse Stock Split
Vaccinex, Inc. Announces Reverse Stock Split
Vaccinex Stock (NASDAQ:VCNX), Dividends
Vaccinex GAAP EPS of -$0.10, revenue of $0.55M
See More Headlines
Receive VCNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/01/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCNX
Employees
38
Year Founded
N/A

Profitability

Net Income
$-19,820,000.00
Pretax Margin
-2,768.80%

Debt

Sales & Book Value

Annual Sales
$280,000.00
Book Value
$1.56 per share

Miscellaneous

Free Float
5,510,000
Market Cap
$10.62 million
Optionable
Not Optionable
Beta
1.14
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Maurice Zauderer Ph.D. (Age 77)
    Co-Founder, CEO, President & Director
    Comp: $400.7k
  • Dr. Elizabeth E. Evans Ph.D. (Age 51)
    COO and Senior VP of Discovery & Translational Medicine
    Comp: $255.46k
  • Dr. Ernest S. Smith Ph.D. (Age 51)
    Senior VP of Research & Chief Scientific Officer
    Comp: $284.02k
  • Mr. Scott E. Royer C.F.A. (Age 49)
    M.B.A., Chief Financial Officer
    Comp: $242.15k
  • Dr. John E. Leonard Ph.D. (Age 76)
    Senior Vice President of Development














VCNX Stock Analysis - Frequently Asked Questions

How have VCNX shares performed in 2023?

Vaccinex's stock was trading at $9.6675 at the beginning of 2023. Since then, VCNX shares have decreased by 91.5% and is now trading at $0.8201.
View the best growth stocks for 2023 here
.

Are investors shorting Vaccinex?

Vaccinex saw a increase in short interest in November. As of November 15th, there was short interest totaling 50,400 shares, an increase of 32.3% from the October 31st total of 38,100 shares. Based on an average daily volume of 631,200 shares, the short-interest ratio is currently 0.1 days. Approximately 0.8% of the company's shares are sold short.
View Vaccinex's Short Interest
.

When is Vaccinex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our VCNX earnings forecast
.

How were Vaccinex's earnings last quarter?

Vaccinex, Inc. (NASDAQ:VCNX) posted its quarterly earnings data on Monday, November, 8th. The company reported ($2.55) earnings per share for the quarter, topping the consensus estimate of ($4.35) by $1.80. The firm had revenue of $0.05 million for the quarter.

When did Vaccinex's stock split?

Vaccinex's stock reverse split on Tuesday, September 26th 2023. The 1-15 reverse split was announced on Tuesday, September 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

When did Vaccinex IPO?

(VCNX) raised $45 million in an IPO on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

Who are Vaccinex's major shareholders?

Vaccinex's stock is owned by a number of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (24.78%), Worth Venture Partners LLC (16.31%), Armistice Capital LLC (15.45%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Albert Friedberg, Jacob B Frieberg, Maurice Zauderer and Strydonck Gerald E Van.
View institutional ownership trends
.

How do I buy shares of Vaccinex?

Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:VCNX) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -